The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

London stocks closed little changed on Friday after a week marked by central bank policy moves, shifting economic signals and ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

The pound rose to USD1.3450 late on Friday afternoon in London, compared to USD1.3412 at the equities close on Thursday. The euro traded at USD1.1666, higher against USD1.1631. Against the yen, the ...

The Trump administration seeks higher overseas drug prices as it plans to impose Most Favored Nation policy, which aims to ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

The FTSE 100 edged down on Friday on a mixed day for European equities despite new optimism about an end to the war between ...

The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere to ...

In its new guidelines, the American Heart Association says not all ultraprocessed foods are so bad — such as whole grain breads, low-sugar yogurts, tomato sauces, and nut or bean-based spreads. The ...

CureVac and GSK will receive $740 million and single-digit royalties on COVID-19 vaccine sales in the U.S. going forward.

CureVac N.V., a multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA ...